Sistema de Salut de Catalunya
Institut Català de la Salut
[Pathak N] Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada. [Oliveira M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-03-20T10:44:08Z
2025-03-20T10:44:08Z
2025
Breast cancer; Camizestrant; Estrogen receptor
Cáncer de mama; Camizestrant; Receptor de estrógeno
Càncer de mama; Camizestrant; Receptor d'estrògens
Oral selective estrogen receptor degraders (SERDs) are pure estrogen receptor antagonists that have the potential to overcome common resistance mechanisms to endocrine therapy in estrogen receptor–positive breast cancer. There are currently five oral SERDs in published and ongoing clinical trials—elacestrant, camizestrant, giredestrant, imlunestrant, and amcenestrant—with more in development. They offer a reasonably well-tolerated oral therapy option with low discontinuation rates in studies. This review summarizes the currently available literature on this new class of drugs.
Article
Published version
English
Estrògens - Antagonistes - Ús terapèutic; Antihormones - Ús terapèutic; Mama - Càncer - Tractament; Medicaments antineoplàstics - Ús terapèutic; CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormone Antagonists::Estrogen Receptor Modulators::Selective Estrogen Receptor Modulators; Other subheadings::Other subheadings::/therapeutic use; DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Hormonal; CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormone Antagonists::Estrogen Antagonists::Estrogen Receptor Antagonists; Other subheadings::Other subheadings::/therapeutic use; COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::moduladores de los receptores de estrógenos::moduladores selectivos de los receptores de estrógenos; Otros calificadores::Otros calificadores::/uso terapéutico; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::antineoplásicos hormonales; COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::antagonistas de estrógenos::antagonistas de receptores estrogénicos; Otros calificadores::Otros calificadores::/uso terapéutico
Annual Reviews
Annual Review of Medicine;76
https://doi.org/10.1146/annurev-med-052423-122001
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]
